scholarly journals Literature Review THE EFFECT OF STRESS DURING PREGNANCY ON PREGNANCY OUTCOMES

2021 ◽  
Vol 11 (1) ◽  
pp. 28-31
Author(s):  
DEWI PITRIAWATI ◽  
Dwi Sri Rahandayani

Pandemi CoViD-19 menuntut banyak orang untuk mampu beradaptasi secara significant terhadap segala perubahan yang  ada. Ibu hamil pun dituntut untuk bisa beradaptasi dengan segala sesuatu yang terjadi, hal ini tak jarang membuat ibu hamil beresiko mengalami masalah atau gangguan psikologis karena proses adaptasi yang memerlukan banyak energi. Masalah atau gangguan psikologis seperti stres dikhawatirkan akan memberikan efek terhadap kondisi kesehatan ibu dan janin di masa kehamilan. Penelitian ini bertujuan untuk mengetahui pengaruh stres kehamilan terhadap outcome kehamilan. Metode penelitian ini adalah literatur review yang melakukan penelusuran di gscholar dan pubmed dengan sistem eliminasi artikel sesuai kriteria inklusi, eksklusi dan kelayakan literatur. Penelusuran pustaka dalam penelitian ini berhasil mengidentifkasi 9 artikel yang membahas tentang pengaruh stres di masa kehamilan terhadap outcome kehamilan. Masalah, stres atau gangguan psikologis dalam kehamilan dapat menyebabkan berbagai masalah kesehatan baik bagi ibu maupun janin, oleh karena itu perlunya menjaga kualitas kesehtaan mental ibu selama kehamilan guna kualitas kesehatan ibu dan janin dimasa kehamilan dan masa nifas.

2019 ◽  
Vol 1 (7) ◽  
pp. 5-8
Author(s):  
L. S. Kruglova ◽  
A. A. Osina ◽  
A. A. Khotko

Among patients with psoriasis, approximately 50% are women and almost 75 % of them are under the age of 40 years. Thus, most women with psoriasis have childbearing potential. When pregnancy occurs in 22 % of patients, the activity of psoriasis persists, characteristic of the course before pregnancy, in 23 % of women, the course of the disease worsens. The article provides up-to-date data on the management of pregnant patients with psoriasis. To improve pregnancy outcomes in patients with psoriasis, it is important to prevent exacerbation of the disease. The choice of drug therapy in this case is based on an assessment of the ratio of the risk of undesirable effects of the drugs on the developing fetus and the risk of the development of exacerbation of psoriasis, which can cause an adverse pregnancy outcome. Despite the fact that the available clinical experience of using genetically engineered drugs is still limited, with a certain degree of confidence we can say that there is no increase in the risk of adverse pregnancy outcomes associated with therapy with certolizumab pegol.


2021 ◽  
Vol 9 (4) ◽  
pp. 63-70
Author(s):  
Yu.A. Kosolapova ◽  
◽  
L.A. Morozov ◽  
E.V. Inviyaeva ◽  
M.I. Makieva ◽  
...  

2020 ◽  
Vol 13 ◽  
pp. 175628482095259
Author(s):  
Birgit Terjung ◽  
Renate Schmelz ◽  
Robert Ehehalt ◽  
Jochen Klaus ◽  
Jana Knop ◽  
...  

Background: Crohn’s disease (CD) and ulcerative colitis (UC) commonly affect women in their childbearing years. Vedolizumab (VDZ) is approved for treatment of moderate-to-severe CD and UC, but there is a knowledge gap regarding its use during pregnancy. This targeted literature review describes available evidence on safety of VDZ in pregnant patients in order to offer physicians a detailed and balanced view on persistent data during their decision-making process for an individualized treatment concept. Methods: The search included literature from the MEDLINE database and abstracts of five gastroenterological conferences published until November 2019. Publications were included if pregnancy outcomes in women receiving VDZ or neonatal outcomes in newborns of women previously exposed to VDZ were reported. Results: Out of 196 initially identified records, 18 publications reporting results of five different studies were identified. In total, for 213 of 284 VDZ-exposed documented pregnancies the following pregnancy outcomes were reported: 167 live births (172 infants due to twin births), 1 stillbirth, 35 miscarriages, 10 elective terminations (1 due to detected Down syndrome). Furthermore, during pregnancy, the following complications were observed: seven cases of (pre) eclampsia, three cases of premature rupture of membranes and one case each of placenta previa, chorioamnionitis, pneumonia, first-trimester bleeding, cholestasis, sepsis, or neonatal intraventricular hemorrhage. Based on 172 infants, 30 preterm deliveries (17.4%), 9 cases of low birth weight (5.2%), 5 infections (2.9%), and 6 cases (3.8%) with congenital anomalies were reported. Conclusion: There was no evidence for safety concerns regarding pregnancy outcomes associated with VDZ therapy. Due to the limited scope of included records, further research is needed to understand the safety profile regarding the use of VDZ during pregnancy.


2020 ◽  
Vol 23 (13) ◽  
pp. 2434-2444 ◽  
Author(s):  
Janelle M James-McAlpine ◽  
Lisa Vincze ◽  
Jessica J Vanderlelie ◽  
Anthony V Perkins

AbstractObjective:To assess the quantity and focus of recent empirical research regarding the effect of micronutrient supplementation on live birth outcomes in low-risk pregnancies from high-income countries.Design:A systematic quantitative literature review.Setting:Low-risk pregnancies in World Bank-classified high-income countries, 2019.Results:Using carefully selected search criteria, a total of 2475 publications were identified, of which seventeen papers met the inclusion criteria for this review. Data contributing to nine of the studies were sourced from four cohorts; research originated from ten countries. These cohorts exhibited a large number of participants, stable data and a low probability of bias. The most recent empirical data offered by these studies was 2011; the most historical was 1980. In total, fifty-five categorical outcome/supplement combinations were examined; 67·3 % reported no evidence of micronutrient supplementation influencing selected outcomes.Conclusions:A coordinated, cohesive and uniform empirical approach to future studies is required to determine what constitutes appropriate, effective and safe micronutrient supplementation in contemporary cohorts from high-income countries, and how this might influence pregnancy outcomes.


2022 ◽  
Author(s):  
Huijing Zhang ◽  
Xiaoying Zhu ◽  
Jinling Kang ◽  
Huixia Yang ◽  
Yu Sun

Abstract Objection To explore the clinical features and prognosis of non-visualization of fetal gallbladder (NVFGB). Methods 65 cases diagnosed of NVFGB in the Peking University First Hospital was collected retrospectively from January, 2019 to December, 2020. Results 49 cases were successfully followed up. Among them, the gallbladder of 21 fetuses (42.9%) was visible later, either in the later pregnancy or after birth. In the rest 28 cases (57.1%), the gallbladders were not seen during the whole pregnancy. 11 of 28 fetuses (39.3%) with NVFGB were complicated with other structure anomaly. In the remaining 17 cases of isolated NVFGB (60.7%), one case was diagnosed of congenital biliary atresia, 3 cases of small gallbladder, 1 case of gallstone and one case of irregular size of gallbladder. There are 9 cases who underwent prenatal diagnosis, with 4 cases of abnormal result. Conclusion Prenatal ultrasound plays a role in the early recognize of abnormal gallbladder, which will improve the postnatal prognosis.


2020 ◽  
Vol 11 ◽  
pp. 204201882092056 ◽  
Author(s):  
Ruofan Qi ◽  
Tin Chiu Li ◽  
Xiaoyan Chen

Background: Implantation is initiated when the blastocyst attaches to the endometrium during the peri-implantation period, and appropriate neovascularization is a prerequisite for the success of the subsequent process. The role of the renin–angiotensin system (RAS) in regulation of blood pressure and hydro-electrolyte balance has long been recognized, while its role in the peri-implantation endometrium remains unclear. This manuscript discusses endometrial RAS and its possible pathways in regulating endometrial angiogenesis and its influence on subsequent pregnancy outcomes. Methods: A comprehensive search of electronic databases was carried out to identify relevant published articles, and a literature review was then performed. Using immunohistochemistry, we also performed a pilot study to examine expression of angiotensin II receptors, including angiotensin II type 1 (AT1) receptor (AT1-R) and angiotensin II type 2 (AT2) receptor (AT2-R) in the human endometrium around the time of implantation. Results: The results of the pilot study showed expression of AT1-R and AT2-R in all endometrial compartments (luminal epithelium, glandular epithelium, stroma cells, and blood vessels), and altered expression was witnessed in women with recurrent miscarriage when compared with fertile control women from our preliminary result. Conclusion: Altered vasculature of the endometrium in the peri-implantation period is detrimental to implantation and may lead to recurrent miscarriage. Being an angiogenic mediators, endometrial RAS may play a role around the time of embryo implantation, affecting subsequent pregnancy outcomes.


Sign in / Sign up

Export Citation Format

Share Document